Medical Oncology (Final Exam) Flashcards by Jessyka Yard

these are used to treat ________
5-Fluorouracil (FLUOROURACIL)
Capecitabine (XELODA)
Irinotecan (CAMPTOSAR)
Cetuximab (ERBITUX)
Panitumumab (VECTIBIX)
Pembrolizumab (KEYTRUDA)
Nivolumab (OPDIVO)

colorectal cancer
* 5 capelin I caught Panned Pecked Nivea

How well did you know this?

Not at all

Perfectly

this is used for treatment of ardenocarcinoma of colon and rectum administered in combination with leucovorin alone or in combination with leucovorin and oxaliplatin or irinotecan. Gene involved is DPD*2A / splicing mutation

5-Fluorouracil (FLUOROURACIL)

How well did you know this?

Not at all

Perfectly

this is used for treatment of metastatic colorectal cancer when treatment with fluorpyrimidine therapy alone is preferred. Gene involved is DPD*2A

Capecitabine (XELODA)

How well did you know this?

Not at all

Perfectly

this is used for treatment of metastatic colorectal cancer in combination with 5-FU and leucovorin. Gene involved is UGT1A1*28

Irinotecan (CAMPTOSTAR)

How well did you know this?

Not at all

Perfectly

this is used to treatment of RAS wild-type, EGFR-expressing metastatic colorectal cancer. Genes involved include KRAS/NRAS/EGFR

Cetuximab (ERBITUX)

How well did you know this?

Not at all

Perfectly

this used for treatment of wild-type KRAS/NRAS metastatic colorectal cancer. Genes involved include KRAS/NRAS/EGFR

Panitumumab (VECTIBIX)

How well did you know this?

Not at all

Perfectly

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 12 and 13 of exon __

How well did you know this?

Not at all

Perfectly

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 59 and 61 of exon __

How well did you know this?

Not at all

Perfectly

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 117 and 146 of exon __

How well did you know this?

Not at all

Perfectly

this is used for treatment of unrespectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and PD-L1 (CD274) expression that has progressed following Tx with fluoropyrimidine, oxaliplatin and irinotecan. Genes involved include MSI/MLH1/MSH2/MSH6/PMS2/CD274

Pembrolizumab (KEYTRUDA)

How well did you know this?

Not at all

Perfectly

this is used for treatment of micro satellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metatstatic colorectal cancer and PD-L1 (CD274) expression that has progressed following Tx with a fluoropyrimidine, oxaliplatin and irinotecan. Genes involved include MSI/MLH1/MSH2/MSH6/PMS2/CD274

Nivolumab (OPDIVO)

How well did you know this?

Not at all

Perfectly

these two drugs are used to treat KRAS G12C-mutated locally advanced or metastatic lung cancer

Sotorasib (LUMAKRAS) and Adagrasib (KRAZATI)

How well did you know this?

Not at all

Perfectly

these two drugs are used to treat lung cancer where tutors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

gefitinib (IRESSA) and Erlotinib (TARCEVA)

How well did you know this?

Not at all

Perfectly

true/false: getfitinib (IRESSA) and Erlotinib (TARCEVA) is effective for exon 20 mutations

false

How well did you know this?

Not at all

Perfectly

these two drugs are used to treat lung cancer where tutors have non-resistant EGFR mutations including exon 19 deletions or exon 21 (L858R) substitution mutations

Afatinib (GILOTRIF) and Dacomitinib (VIZIMPRO)

How well did you know this?

Not at all

Perfectly

true/false: Afatinib (GILOTRIF) and Dacomitinib (VIZIMPRO) are effective for exon 20 mutations

false

How well did you know this?

Not at all

Perfectly

this is used to treat lung cancer where tutors have EGFR exon 19 deletions or exon 21 L858R mutations or treatment of metastatic EGFR T790M-positive lung cancer where disease has progressed on or after EGFR TKI Tx

Osimertinib (TAGRISSO)

How well did you know this?

Not at all

Perfectly

true/false: Osimertinib (TAGRISSO) is effective for exon 20 mutations

true

How well did you know this?

Not at all

Perfectly

this is used to treat locally advanced lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy

Mobocertinib (EXKIVITY)

How well did you know this?

Not at all

Perfectly

true/false: Mobocertinib (EXKIVITY) is effective for exon 20 mutations

true

How well did you know this?

Not at all

Perfectly

this is used for treatment of lung cancer that is ALK positive or ROS1 positive

Crizitonib (XALKORI)

How well did you know this?

Not at all

Perfectly

this is used for treatment of ALK-positive lung cancer that have inadequate response to crizotinib

Certinib (ZYKADIA)

How well did you know this?

Not at all

Perfectly

these two drugs are used for treatment of ALK-positive lung cancer that has progressed with crizotinib. more potent and selective second generation ALK inhibitors

Alectinib (ALECENSA) and Brigatinib (ALUNBRIG)

How well did you know this?

Not at all

Perfectly

this is used for treatment of ALK-positive lung cancer that has progressed on crizotinib, certinib and/or alectinib

Lorlatinib (LORBRENA)

How well did you know this?

Not at all

Perfectly

this is used for treatment of lung cancer with EGFR/ALK aberrations with disease progression on previous co-therapy

Ramucirumab (CYRAMZA)

this is used for treatment of lung cancer where tutors are ROS1-positive or have a neurotrophic tyrosine receptor kinase (NRTK) gene fusion

Entrectinib (ROZLYTREK) * ROZ and TREK mimic genes affected (ROS1 and N"TRK"

this is used for treatment of lung cancer with BRAF V600E/K mutation. may also have an affect in patients with G6PD deficiency

Dabrafenib (TAFINLAR) * BRAF gene, daBRAFenib

these two drugs are used for treating lung cancer where tumors have mutations that leads to MET exon 14 skipping

Capmatinib (TABRECTA) and Tepotinib (TEPMETKO) * second drug has MET in name therefore MET gene

these two drugs are used to treat RET-fusion positive lung cancer

Selpercatinib (RETEVMO) and Pralsetinib (GAVRETO) * RET gene, RET in brand names

these three drugs treat lung cancer where tumors have high PD-L1 (CD274) expression with no EGFR or ALK genomic tumour aberrations

Pembrolizumab (KEYTRUDA) and Nivolumab (OPDIVO) and Atezolizumab (TECENTRIQ) * pecking Nivea causes atopic dermatitis *

this drug treats lung cancer where tumors have high PD-L1 (CD274) expression with no EGFR, ALK or ROS1 aberrations

Cemiplimab (LIBTAYO) * pecking Nivea causes atopic dermatitis *

these two drugs treats lung cancers that express (not high levels) PD-L1 (CD274) with no EGFR or ALK genomic tumour aberrations

Durvalumab (IMFINZI) and Ipilimumab (YERVOY) * pecking Nivea causes atopic dermatitis *

these twi drugs are used to treat lung cancer with no EGFR or ALK genomic tumour aberrations

Pemetrexol (ALIMTA) and Tremelimumab (IMJUDO) * pem trem *

these two drugs are indicated for breast cancer and are associated with the DPD gene mutation

5-Fluorouracil (FLUOROURACIL) & Capecitabine (XELODA) * 5 capelin * <- same as colorectal cancer tx

this drug is used for treatment of estrogen receptor positive metastatic breast cancer. mutation/clinical utility is ESR1/ESR2/CYP2D6. this is also a prodrug

Tamoxifen (NOLVADEX) * ik CYP2D6 therefore seen tamoxifen in practice

this drug is used for tx of estrogen receptor positive metastatic breast cancer. gene/clinical utility is ESR1/ESR2

Toremifene (FARESTON)

this drug is used for tx of post-menopausal women with ER-postiive early breast cancer who have received initial adjuvant tamoxifen therapy. Mutation/clinical utility is ESR1/ESR2

Exemestane (no brand name)

this drug is used two drugs are used for tx of post-menopausal women with HR-postiive early breast cancer or advanced breast cancer. Mutation/clinical utility is ESR1/ESR2/PGR

Anastrozole & Letrozole (FEMARA) * Ana Letgo

this is used for treatment of HR-positive, HER-negative advanced breast cancer in post-menopausal women not previously treated with endocrine therapy. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

Fulvestrant (FASLODEX) * full even palpating ribs *

this is used for treatment of post-menopausal women with advanced HR-positive, HER2-negative breast cancer in combination with exemestane after failure of tx with anastrozole or letrozole. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

Everolimus (AFINITOR) * full even palpating ribs *

these two drugs are used for treatment of HR-postiive, HER2-negative advanced or metastatic breast cancer. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

Palbociclib (IBRANCE) & Ribociclib (KISQALI) * full even palpating ribs *

this is used for tx of women with HR-positive, HER2-negative breast cancer and a high Ki-67 (early) biomarker score as a mono therapy or in combination with other medications. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/MKI67

Abemaciclib (VERZENIO) * Abe *

this is used for tx of HR-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer following progression on an endocrine-based regimen in post-menopausal women and men. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/PIK3CA

Alpelisib (PIQRAY) * Alp*

these two drugs are used for tx of deleterious or suspected deleterious gremlin BCRA-mutates (gBCRAm) HER2-negative breast cancer. mutation/clinical utility is ERBB2/BCRA1/BCRA2`

olaparib (LYNPARAZA) & talazoparib (TALZENNA) * Olaf talks *

this drug is sued to treat HER2-positive metastatic breast cancer mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

Trastuzumab (HERCEPTIN)

this drug is used to treat HER2-positive metastatic breast cancer who have not received prior anti-HER2 tx or chemotherapy in combination with other medications. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

Pertuzumab (PERJETA)

rdxthis drug is used to treat metastatic HER2-positive breast cancer (combination therapy) after receiving two or more prior anti-HER2 regimens. mutation/clinical utility is ERBB2

Margetuximab (MARGENZA)

this drug is used to treat advanced unrespectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine after receiving one or more prior anti-HER2 based regimens. mutation/clincal utility is ERBB2

Tucatinib (TUKYSA)

this drug is used as extended adjuvant tx of early stage HER2-positive breast cancer to follow adjuvant trastuzumab-based therapy. mutation/clinical utility is ERBB2

Neratinib (NERLYNX)

this drug is used to treat HER2-positive advanced or metastatic breast cancer (w/ Capecetabine) after tx with anthracycline and trastuzumab or tx of HR-positive, HER2-positive metastatic breast cancer (w/ Letrozole) in post-menopausal women. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/HLA-DQA1/HLA-DRB1

Lapatinib (TYKERB)

this drug is used for treatment of metastatic triple negative breast cancer (mTNBC) where tumours express PD-L1 (CD274). mutations/clincial utility is ERBB2/ESR1/ESR2/PGR/CD274

Atezoliumab (TECENTRIQ)

does Tucatinib (TUKYSA) cover HER2-negative or positive BC

positive

does Alpelisib (PIQRAY) cover HER2-negative or positive BC

negative

does Fulvestrant (FASLODEX) cover HER2-negative or positive BC

negative

does Lapatinib (TYKERB) cover HER2-negative or positive BC

positive

does Neratinib (NERLYNX) cover HER2-negative or positive BC

positive

does Palbociclib (IBRANCE) cover HER2-negative or positive BC

negative

does Margetuximab (MARGENZA) cover HER2-negative or positive BC

positive

does Everoliumus (AFINITOR) cover HER2-negative or positive BC

negative

does Olaparib (LYNPARZA) cover HER2-negative or positive BC

negative

does Trastuzumab (HERCEPTIN) cover HER2-negative or positive BC

positive

does Talazoparib (TALZENNA) cover HER2-negative or positive BC

negative

does Abemaciclib (VERENZO) cover HER2-negative or positive BC

negative

does Ribociclib (KISQALI) cover HER2-negative or positive BC

negative

does Pertuzumab (PERJETA) cover HER2-negative or positive BC

positive

these drugs are used to treat ________ cancer - Olaparib (LYMPARZA) - Rucaparib (RUBRACA) - Mirvetuximab Soravtansine (ELAHERE)

ovarian * Olaf's ruckus mirrored

these two drugs are used to treat deleterious gremlin or somatic BCRA-mutated advanced epithelial ovarian, Fallopian tube or primary peritoneal cancer. mutation/clincal utility is BCRA1/BCRA2

Olaparib (LYNPARZA) & Rucaparib (RUBRACA)

this drug is used to treat folate receptor alpha (FR-alpha) positive, platinum resistant epithelial ovarian, Fallopian tube or primary peritoneal cancer. mutation/clinical utility is FOLR1

Mirvetuximab Soravtansine (ELAHERE)

these drugs are used to treat _______ cancer - Dostarlimab (JEMPERLI) - Lenvatinib (LENVIMA)

endometrial * STAR LENses

this drug is used to treat mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen mutation/clinical utility is MLH1/MSH2/MSH6/PMS2/CD274

Dostarlimab (JEMPERLI) * has P in brand name therefore MSI-H/dMMR are "P"resent

this drug is used to treat advanced endometrial carcinoma (combination with pembrolizumab), that is NOT micro satellite instability high (MSI-H) or mismatch repair deficient (dMMR) with disease progression following prior systemic therapy. mutation/clinical utility is MSI/MLH1/MSH2/MSH6/PMS2

Lenvatinib (LENVIMA)

this drug used used to treat unrespectable or metastatic melanoma with BRAF V600E mutation mutation/clinical utility: BRAF

Vemurafenib (ZELBORAF) * Debra & Cora's femurs met Cobi's bin

these 5 drugs are used to treat melanoma with a BRAF V600E or K mutation. mutation/clinical utility: BRAF

Dabrafenib (TAFINLAR) Encorafenib (BRAFTOVI) Trametinib (MEKINIST) Cobimetinib (COTELLIC) Binimetinib (MEKTOVI) * Debra & Cora's femurs met Cobi's bin

this drug is used to treat BRAF V600 mutation-positive unrespectable or metastatic melanoma (combination therapy with cobimetinib and vemurafenib) mutation/clincal utility is BRAF/CD274

Atezolizumab (TECENTRIQ)

this drug is used to treat HLA-A*02:01-positive adult patients with unrespectable or metastatic UVEAL melanoma (occurs in the tissue of the eye. it is a bisepcific gp100 peptide HLA-A*02:01 directed CD3 T-cell engager resulting in direct lysis of uveal melanoma tumour cells mutation/clinical utility is HLA-A*02:01

Tebentafusp (KIMMTRAK)

this drug is used to treat gastric adenocarcinoma administered as a component of platinum-containing multi drug chemotherapy regimen. mutation/clincal utility is DPD (*2A splicing mutation)

5-Fluorouracil (FLUOROURACIL)

this drug is used to treat unrespectable or metastatic gastrointestinal stroll tutors (GIST) harbouring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations mutation/clincal utility is PDGFRA

Avapritinib (AYVAKIT)

this drug is used to treat recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tutors express PD-L1 (CD274) mutation/clinical utility is CD274

Pembrolizumab (KEYTRUDA)

this drug is used to treat somatostatin receptor (SSTR)-positive gastroenteropancreatitc neuroendocrine tutors (GEP-NETs) mutation/clinical utility is SSTR1/SSTR2/SSTR3/SSTR4/SSTR5

Lutetium Dotatate (LUTATHERA)

this is used for treatment of advanced or metastatic anapaestic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory loco regional treatment options in combination with dabrafenib mutation/clinical utility is BRAF

trametinib (MEKINIST) * same as melanoma

this is used for treatment of advanced or metastatic urothelial carcinoma in patents not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 (CD274) mutation/clinical utility is CD274

Atezolizumab (TECENTRIQ)

this is used for treatment of advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 mutations and progressed during or following at least one line of platinum-containing chemotherapy mutations/clinical utility is FGFR2/FGFR3/CYP2C9

Erdafitinib (BALVERSA)

which CYP2C9 mutations have reduced enzyme activity regarding Erdafitinib (BALVERSA)

CYP2C9*3/*3 and *2/*3

this drug is used to treat gremlin BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) AND maintenance tx of deleterious or suspected deleterious gBCRAm metastatic pancreatic adenocarcinoma. mutation/clinical utility is BCRA1/BCRA2

Olaparib (LYNPARZA)

these two drugs are used to treat unrespectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion mutation/clinical utility is FGFR2

Infigratinib (PEMAZYRE) & PEMIGATINIB (TRUSLETIQ)

this is used to treat von Hippel-Lindau (VHL) disease, associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours (pNET). mutation/clinical utility is VHL/CYP2C19/UGT2B17

Belzutifan (WELIREG)

which enzymes are Belzutifan (WELIREG) metabolized by

CYP2C19 and UGT2B17

this is used to treat solid tutors with a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation mutation/clincal utility is NTRK1/NTRK2/NTRK3

Larotrectinib (VITRAKVI)

this is used for treatment of leukemia, lymphoma and solid tumour malignancies which causes elevations of uric acid levels mutation/clincal utility is HLA-B*5801 presence of this increases his for hypersensitivity reactions (SJS/TEN)

Allopurinol (ALOPRIM)

this is used for treatment of plasma uric acid levels in patients with leukemia, lymphoma and solid tumour malignancies who are receiving therapy to result in tumour lysis. mutation/clinical utility is G6PD deficiency of G6PD can result in increased s/e

Rasburicase (FASTURTEC)